Dermatology

Investigators observed that many patients with psoriasis are not actively seeing a primary care physician and would welcome management of their cardiovascular risk factors.

Mark Lebwohl, MD, and Jerry Bagel, MD, MS, review the currently available TNF-α and IL-12/23 inhibitors used to treat plaque psoriasis.

Spearheaded by Dr Bagel, the panel explores the role of phototherapy in the treatment of plaque psoriasis.

Recovery was often deemed rapid, with patients reporting post-surgical pain to be less severe than the pain of their disease.

Both PEARL 1 and PEARL 2 enrolled over 2000 adults and adolescents patients selected from 48 countries.

Prominent dermatologists detail how a biased literature, a lack of education, accessibility issues, and historical wrongdoings have all influenced the study of skin of color.

Investigators believe this could be a good option for patients who did not respond to a first-line biologic, though further research is required.

Investigators added that clinical condition at the time of vaccination and biologic treatment did not influence the humoral response in the enrolled patients.

Investigators suggest that improvements to care could be made based on experiences and recommendations from patients with chronic hand eczema.

Half of all cases of vitiligo occur in childhood, and accessibility to therapy has been an ongoing issue.

Data from the ADQoC Initiative show that patients with AD are often misdiagnosed or the severity of their disease was undertreated.

Dr. Amy Paller and colleagues noted high efficacy rates and minimal adverse events from biologic therapy.

Investigators suggested systemic mental health monitoring could be beneficial for women who have atopic disease before pregnancy.

Investigators called for more studies which feature adequately powered trials of test-guided dietary exclusions.

The topical drug was associated with adverse events that were mainly localized to the application site and mild to moderate in nature.

According to investigators, no previous studies had investigated the expression of IL-38 in patients with vitiligo.

A litany of research has begun to shape the potential benefit of UV treatment for the skin disorder. Experts share what more needs to be known.

Nearly 70% of all vitiligo patients included in the study remained pigmented after systemic immunomodulatory treatment, with no evidence of recurrence of the disease.

To the investigators’ knowledge, the study offers insights into lesion presentations on undiagnosed adults with vitiligo.

Investigators said that patient-reported outcomes from the 2 abrocitinib groups showed greater efficacy than the dupilumab and placebo groups.

Respondents suggested that increasing product availability and demonstrating the consequences of sunburn could increase sun protection among young people.

Dr. Elewski hopes that in the future more clinicians will prescribe biologics such as secukinumab and etancercept for the treatment of psoriasis.

Certain biologics such as infliximab have aided psoriasis patients in the mitigation of symptoms from the COVID-19 virus.

Dr. Desai says that Janus kinase inhibitors present a new mechanism of action, with effects on cytokine signals that signal inflammation in atopic diseases.

Swanson noted the efficacy and safety of dupilumab, which she feels revolutionized patient care.